Rotavirus Vaccine Buffer Systems for Acid Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current rotavirus vaccines face challenges in stability, particularly in low-income countries where transportation and storage are costly and logistically complex, and there is a need for formulations that remain effective for at least 24 months, with existing buffers like citrates and phosphates having limitations in stability and safety.
Innovation Solution
Development of novel liquid rotavirus vaccine compositions using alternative buffer systems such as Magnesium Hydroxide Carbonate, Carbonate-Bicarbonate, and Ammonium-based mixed buffers that provide enhanced stability and acid-neutralizing capacity, allowing the vaccine to maintain potency for up to 2 years without requiring pre-administration of antacids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If traditional buffers like citrates and phosphates are used in rotavirus vaccine formulations, then the vaccine can be stabilized to some extent, but the stability is insufficient for long-term storage (24 months) and requires additional antacid pre-administration
Solution Approach 1:
The patent changes the chemical parameters of the buffer system by replacing traditional citrate and phosphate buffers with alternative buffer systems including magnesium hydroxide carbonate, carbonate-bicarbonate, and ammonium-based mixed buffers. This parameter change achieves enhanced stability for 24-month storage and eliminates the need for antacid pre-administration while maintaining vaccine efficacy
Solution Approach 2:
The patent employs composite buffer systems that combine multiple buffering agents (e.g., magnesium hydroxide carbonate, carbonate-bicarbonate mixtures, ammonium-based combinations) to achieve synergistic effects that provide both long-term stability and sufficient acid-neutralizing capacity without requiring separate antacid administration
2Duration of action of stationary object
If the vaccine formulation is designed for long-term stability (24 months), then global distribution becomes more feasible, but the formulation complexity and cost increase
Solution Approach 1:
By changing the buffer composition parameters to alternative systems (magnesium hydroxide carbonate, carbonate-bicarbonate, ammonium-based buffers), the patent achieves 24-month stability without requiring complex lyophilization processes or multiple stabilizer combinations, thus managing formulation complexity while extending storage duration
3Stability of the object's composition
If alternative buffer systems are used to enhance stability, then the vaccine remains effective for longer periods, but the compatibility and safety profiles need thorough validation
Solution Approach 1:
The alternative buffer systems (magnesium hydroxide carbonate, carbonate-bicarbonate, ammonium-based buffers) are selected because they are physiologically compatible and can self-regulate pH without requiring additional stabilizers or complex formulation components, thereby maintaining reliability while achieving extended stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel buffer systems ensure the stability and efficacy of the rotavirus vaccine for extended periods, facilitating easier and cost-effective global distribution and administration, while avoiding the limitations of traditional buffers like citrates and phosphates.
Implementation Method 1
Rotavirus is an acid-labile virus having a half-life of less than 12 minutes at pH 2.0. It is rapidly inactivated at such acidic pH. Therefore, to prevent inactivation of the virus by gastric acid, antacids or buffers are needed to be administered before or in combination with the oral rotavirus vaccination.
Implementation Method 2
The buffers are pre-mixed in the rotavirus vaccine compositions for use of the invention. Vaccine compositions for use of the invention are stable liquid rotavirus vaccine formulations for use in a method of treatment by oral administration.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Invention provides rotavirus vaccine compositions comprising rotavirus antigens, stabilizers and buffers. The buffers in the invention are pre-mixed in the rotavirus vaccine compositions to neutralize the high acidic pH of the stomach without, requiring separate administration of an antacid before vaccine administration. Vaccine compositions with buffers of the invention are stable liquid rotavirus vaccine formulations for oral administration.